The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (397 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 0.957, 5-year impact factor: 1.953
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0032586754&partnerID=40&md5=87f923ab033918b3cd52ddb9dd32cb66
Keywords: Neuroendocrine Tumors, Octreotide, Pituitary Adenomas, Somatostatin, Somatostatin Receptors, Growth Hormone, Pentetate Indium In 111, Prolactin, Somatomedin C, Diagnostic Agent, Drug Derivative, Pentetic Acid, Radiopharmaceutical Agent, Sdz 215 811, Sdz 215-811, Acromegaly, Adolescent, Adult, Article, Cancer Regression, Carcinoid, Clinical Trial, Controlled Clinical Trial, Controlled Study, Drug Blood Level, Drug Uptake, Female, Growth Hormone Release, Human, Hypophysis Adenoma, Insulinoma, Kidney Carcinoma, Major Clinical Study, Melanoma, Nuclear Magnetic Resonance Imaging, Scintigraphy, Single Photon Emission Computer Tomography, Subcutaneous Drug Administration, Thymoma, Thyroid Carcinoma, Hypophysis Tumor, Metabolism, Middle Aged, Scintiscanning, Indium Radioisotopes, Pituitary Gland, Pituitary Neoplasms,
Affiliations:
Dept. Molec. Clin. Endocrinol. O., Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
References:
Lamberts, S.W.J., Van Der Lely, A.-J., De Herder, W.W., Hofland, L.J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J.C., Landolt, A.M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Ikuyama, S., Nawata, H., Kato, K., Karshima, T., Ibayashi, H., Nagakaki, H., Specific somatostatin receptors on human pituitary adenoma cell membrane (1985) J. Clin. Endocrinol. Metab., 61, p. 666
Reubi, J.C., Heitz, P.U., Landolt, A.M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J.C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F.F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Lamberts, S.W.J., Uitterlinden, P., Schuijff, P.C., Klijn, G.C., Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical "cure" (1988) Clin. Endocrinol., 29, p. 411
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) J. Clin. Endocrinol. Metab., 81, p. 2356
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1990) Endocr. Rev., 12, p. 450
Faglia, G., Bazzoni, N., Spada, A., Arosio, M., Ambrosi, B., Spinelli, F., Sara, R., Lunghi, F., In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of radioiodinated analog of somatostatin ([123-I]SDZ 204-090) (1991) J. Clin. Endocrinol. Metab., 73, p. 850
Ur, E., Mather, S.J., Bomanji, J., Ellison, D., Britton, K.E., Grossman, A.B., Wass, J.A.H., Besser, G.M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Broson-Chazot, F., Houzard, C., Ajzenberg, C., Noucaudie, M., Duet, M., Mundler, O., Marchandise, X., Warnet, A., Somatostatin receptor imaging in somatroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide (1997) Clin. Endocrinol., 47, p. 589
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.-J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Plöckinger, U., Bäder, M., Hopfenmüller, H., Saeger, W., Quabbe, H.-J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E.A., Verhoeff, N.P.L.G., Meylaerts, S.A.G., Miedema, A.R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Colao, A., Di Sarno, A., Landi, M.L., Cirillo, S., Samacchiaro, F., Facciolli, G., Pivonello, R., Lombardi, G., Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage (1997) J. Clin. Endocrinol. Metab., 82, p. 3574
Bakker, W.H., Albert, R., Bruns, C., Breeman, W.A.P., Hofland, L.J., Marbach, P., Pless, J., Krenning, E.P., [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T.W.A., Kwekkeboom, D.J., V'ant Verlaat, J.W., Reubi, J.-C., Krenning, E.P., Lamberts, S.W.J., Croughs, R.J.M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J.-C., Landolt, A.M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
Merola, B., Colao, A., Ferone, D., Selleri, A., Di Sarno, A., Marzullo, P., Biondi, B., Lombardi, G., Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm. Res., 40, p. 149
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue an chiasmal dysfunction from pituitary macroadenomas (1989) J. Neurosurg., 71, p. 687
Chanson, P., Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? (1997) Eur. J. Endocrinol., 136, p. 359
Lamberts, S. W. J., Van Der Lely, A. -J., De Herder, W. W., Hofland, L. J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J. C., Landolt, A. M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Reubi, J. C., Heitz, P. U., Landolt, A. M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J. C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F. F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Ur, E., Mather, S. J., Bomanji, J., Ellison, D., Britton, K. E., Grossman, A. B., Wass, J. A. H., Besser, G. M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. -J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Pl ckinger, U., B der, M., Hopfenm ller, H., Saeger, W., Quabbe, H. -J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E. A., Verhoeff, N. P. L. G., Meylaerts, S. A. G., Miedema, A. R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Bakker, W. H., Albert, R., Bruns, C., Breeman, W. A. P., Hofland, L. J., Marbach, P., Pless, J., Krenning, E. P., [111In-DTPA-D-Phe1] -octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T. W. A., Kwekkeboom, D. J., V'Ant Verlaat, J. W., Reubi, J. -C., Krenning, E. P., Lamberts, S. W. J., Croughs, R. J. M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J. -C., Landolt, A. M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 0.957, 5-year impact factor: 1.953
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0032586754&partnerID=40&md5=87f923ab033918b3cd52ddb9dd32cb66
Keywords: Neuroendocrine Tumors, Octreotide, Pituitary Adenomas, Somatostatin, Somatostatin Receptors, Growth Hormone, Pentetate Indium In 111, Prolactin, Somatomedin C, Diagnostic Agent, Drug Derivative, Pentetic Acid, Radiopharmaceutical Agent, Sdz 215 811, Sdz 215-811, Acromegaly, Adolescent, Adult, Article, Cancer Regression, Carcinoid, Clinical Trial, Controlled Clinical Trial, Controlled Study, Drug Blood Level, Drug Uptake, Female, Growth Hormone Release, Human, Hypophysis Adenoma, Insulinoma, Kidney Carcinoma, Major Clinical Study, Melanoma, Nuclear Magnetic Resonance Imaging, Scintigraphy, Single Photon Emission Computer Tomography, Subcutaneous Drug Administration, Thymoma, Thyroid Carcinoma, Hypophysis Tumor, Metabolism, Middle Aged, Scintiscanning, Indium Radioisotopes, Pituitary Gland, Pituitary Neoplasms,
Affiliations:
Dept. Molec. Clin. Endocrinol. O., Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
References:
Lamberts, S.W.J., Van Der Lely, A.-J., De Herder, W.W., Hofland, L.J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J.C., Landolt, A.M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Ikuyama, S., Nawata, H., Kato, K., Karshima, T., Ibayashi, H., Nagakaki, H., Specific somatostatin receptors on human pituitary adenoma cell membrane (1985) J. Clin. Endocrinol. Metab., 61, p. 666
Reubi, J.C., Heitz, P.U., Landolt, A.M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J.C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F.F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Lamberts, S.W.J., Uitterlinden, P., Schuijff, P.C., Klijn, G.C., Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical "cure" (1988) Clin. Endocrinol., 29, p. 411
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) J. Clin. Endocrinol. Metab., 81, p. 2356
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1990) Endocr. Rev., 12, p. 450
Faglia, G., Bazzoni, N., Spada, A., Arosio, M., Ambrosi, B., Spinelli, F., Sara, R., Lunghi, F., In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of radioiodinated analog of somatostatin ([123-I]SDZ 204-090) (1991) J. Clin. Endocrinol. Metab., 73, p. 850
Ur, E., Mather, S.J., Bomanji, J., Ellison, D., Britton, K.E., Grossman, A.B., Wass, J.A.H., Besser, G.M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Broson-Chazot, F., Houzard, C., Ajzenberg, C., Noucaudie, M., Duet, M., Mundler, O., Marchandise, X., Warnet, A., Somatostatin receptor imaging in somatroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide (1997) Clin. Endocrinol., 47, p. 589
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.-J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Plöckinger, U., Bäder, M., Hopfenmüller, H., Saeger, W., Quabbe, H.-J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E.A., Verhoeff, N.P.L.G., Meylaerts, S.A.G., Miedema, A.R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Colao, A., Di Sarno, A., Landi, M.L., Cirillo, S., Samacchiaro, F., Facciolli, G., Pivonello, R., Lombardi, G., Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage (1997) J. Clin. Endocrinol. Metab., 82, p. 3574
Bakker, W.H., Albert, R., Bruns, C., Breeman, W.A.P., Hofland, L.J., Marbach, P., Pless, J., Krenning, E.P., [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T.W.A., Kwekkeboom, D.J., V'ant Verlaat, J.W., Reubi, J.-C., Krenning, E.P., Lamberts, S.W.J., Croughs, R.J.M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J.-C., Landolt, A.M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
Merola, B., Colao, A., Ferone, D., Selleri, A., Di Sarno, A., Marzullo, P., Biondi, B., Lombardi, G., Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm. Res., 40, p. 149
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue an chiasmal dysfunction from pituitary macroadenomas (1989) J. Neurosurg., 71, p. 687
Chanson, P., Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? (1997) Eur. J. Endocrinol., 136, p. 359
Lamberts, S. W. J., Van Der Lely, A. -J., De Herder, W. W., Hofland, L. J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J. C., Landolt, A. M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Reubi, J. C., Heitz, P. U., Landolt, A. M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J. C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F. F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Ur, E., Mather, S. J., Bomanji, J., Ellison, D., Britton, K. E., Grossman, A. B., Wass, J. A. H., Besser, G. M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. -J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Pl ckinger, U., B der, M., Hopfenm ller, H., Saeger, W., Quabbe, H. -J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E. A., Verhoeff, N. P. L. G., Meylaerts, S. A. G., Miedema, A. R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Bakker, W. H., Albert, R., Bruns, C., Breeman, W. A. P., Hofland, L. J., Marbach, P., Pless, J., Krenning, E. P., [111In-DTPA-D-Phe1] -octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T. W. A., Kwekkeboom, D. J., V'Ant Verlaat, J. W., Reubi, J. -C., Krenning, E. P., Lamberts, S. W. J., Croughs, R. J. M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J. -C., Landolt, A. M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas
The aim of this study was to compare the pituitary In-111-DTPA-D-Phe(1)-octreotide uptake measured in 49 patients subjected to the scintigraphy for SS-R expressing tumors not located in the sellar region with that measured in 38 patients with pituitary adenomas. The 87 subjects enrolled in this study were divided into two groups: the first included SSR-expressing tumors (SS-ET), 10 thymomas, 13 differentiated thyroid carcinomas, 4 carcinoids, 5 neuroendocrine tumors, 5 insulinomas, 6 melanomas, 2 renal carcinomas, 2 pheocromocytomas, and 2 parathyroid tumors, while the second included pituitary adenomas, 25 GH-secreting, 4 GH/PRL-mixed and 9 clinically nonfunctioning adenomas (NFA). Planar and single-photon-emission tomography images of the head were obtained 2-4 and 24 hours after the injection of 77-103 MBq of In-111-DTPA-D-Phe(1)-octreotide and pituitary uptake was measured by the region of interest method. A 4 point score was used to grade the pituitary-to-blood (T-to-B) ratios: 0=negative; 1=faint (T-to-B=3.5). In patients with pituitary adenomas, the percent suppression of GH and alpha-subunit levels after 6-12 months of octreotide treatment (0.3-0.6 mg/day) was correlated to T-to-B ratios. After 2-4 hr from injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in 2 out of 49 SS-ET (4%), 18 out of 29 acromegalics (62%) and 6 NFA (66.6%), while a faint uptake was detected in 4 SS-ET (8%), 8 GH-secreting adenomas (27.5%) and 3 NFA (33.3%). Negative scan was detected in the remaining 43 SS-ET (87.7%) and 3 GH-secreting microadenomas (10.3%). 24 hr after injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in SS-ET (10.2%), 21 GH-secreting adenomas (72.4%), and 9 NFA (100%) while a faint uptake was detectable in 15 SS-ET (30.6%), and 6 GH-secreting adenomas (20.7%). No uptake was visualized in 29 SS-ET, and 2 GH-secreting adenomas. By MRI a pituitary tumor was shown in the 2 SS-ET with early moderate tracer uptake. Normalization of circulating GH/IGF-I levels and suppression of alpha-subunit levels was achieved in 16 of 18 acromegalics (88.9%) and 5 of 6 NEA-bearing patients, respectively, with scan scored 2-3 at early images. Eleven acromegalics (37.9%) and 2 NFA (22.2%) displayed significant tumor shrinkage (greater than or equal to 30% of baseline size) during long-term octreotide therapy. Both in GH-secreting and in NEA, a significant correlation was found between percent GH or alpha-subunit suppression after 6-12 months of octreotide therapy and T-to-B ratios both in early (r=0.626; p
The aim of this study was to compare the pituitary In-111-DTPA-D-Phe(1)-octreotide uptake measured in 49 patients subjected to the scintigraphy for SS-R expressing tumors not located in the sellar region with that measured in 38 patients with pituitary adenomas. The 87 subjects enrolled in this study were divided into two groups: the first included SSR-expressing tumors (SS-ET), 10 thymomas, 13 differentiated thyroid carcinomas, 4 carcinoids, 5 neuroendocrine tumors, 5 insulinomas, 6 melanomas, 2 renal carcinomas, 2 pheocromocytomas, and 2 parathyroid tumors, while the second included pituitary adenomas, 25 GH-secreting, 4 GH/PRL-mixed and 9 clinically nonfunctioning adenomas (NFA). Planar and single-photon-emission tomography images of the head were obtained 2-4 and 24 hours after the injection of 77-103 MBq of In-111-DTPA-D-Phe(1)-octreotide and pituitary uptake was measured by the region of interest method. A 4 point score was used to grade the pituitary-to-blood (T-to-B) ratios: 0=negative; 1=faint (T-to-B=3.5). In patients with pituitary adenomas, the percent suppression of GH and alpha-subunit levels after 6-12 months of octreotide treatment (0.3-0.6 mg/day) was correlated to T-to-B ratios. After 2-4 hr from injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in 2 out of 49 SS-ET (4%), 18 out of 29 acromegalics (62%) and 6 NFA (66.6%), while a faint uptake was detected in 4 SS-ET (8%), 8 GH-secreting adenomas (27.5%) and 3 NFA (33.3%). Negative scan was detected in the remaining 43 SS-ET (87.7%) and 3 GH-secreting microadenomas (10.3%). 24 hr after injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in SS-ET (10.2%), 21 GH-secreting adenomas (72.4%), and 9 NFA (100%) while a faint uptake was detectable in 15 SS-ET (30.6%), and 6 GH-secreting adenomas (20.7%). No uptake was visualized in 29 SS-ET, and 2 GH-secreting adenomas. By MRI a pituitary tumor was shown in the 2 SS-ET with early moderate tracer uptake. Normalization of circulating GH/IGF-I levels and suppression of alpha-subunit levels was achieved in 16 of 18 acromegalics (88.9%) and 5 of 6 NEA-bearing patients, respectively, with scan scored 2-3 at early images. Eleven acromegalics (37.9%) and 2 NFA (22.2%) displayed significant tumor shrinkage (greater than or equal to 30% of baseline size) during long-term octreotide therapy. Both in GH-secreting and in NEA, a significant correlation was found between percent GH or alpha-subunit suppression after 6-12 months of octreotide therapy and T-to-B ratios both in early (r=0.626; p
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas
| ▼ Clinical Oncology |
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas
Other filter: ([btitle,keywords] "Neuroendocrine Tumor ...
Verde F, Galatola R, Romeo V, Perillo T, Liuzzi R, Camera L, Klain M, Modica R, Faggiano A, Napolitano V, Colao A, Brunetti A, Maurea S
* Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences (19 views)
Neuroendocrinology (ISSN: 0028-3835linking), 2021; 111(7): 696-704.
Impact Factor: 4.271
View Export to BibTeX Export to EndNote
Lastoria S, Marciello F, Faggiano A, Aloj L, Caraco C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De LucaL, Fonti R, Napolitano V, Colao A
* Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) (259 views)
Endocrine (ISSN: 1355-008x), 2016 Jun; 52(3): 488-494.
Impact Factor: 3.131
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (334 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, Degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML
* Rare diseases in clinical endocrinology: A taxonomic classification system (1216 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2015; 38(2): 193-259.
Impact Factor: 1.994
View Export to BibTeX Export to EndNote
Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M
* Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma (333 views)
World J Radiol (ISSN: 1949-8470, 1949-8470electronic, 1949-8470linking), 2014 Oct 28; 6(10): 840-845.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (722 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (2014 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (354 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (541 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (432 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
View Export to BibTeX Export to EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (1177 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
View Export to BibTeX Export to EndNote
Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, Ruvo M, Gioia M, Rizzarelli E, Coletta M
* Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity (455 views)
J Mol Biol (ISSN: 1089-8638, 0022-2836, 1089-8638electronic), 2009 Feb 6; 385(5): 1556-1567.
Impact Factor: 3.871
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (572 views)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (479 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
View Export to BibTeX Export to EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (334 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
View Export to BibTeX Export to EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (323 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Vitale RM, Pedone C, De Benedetti PG, Fanelli F
* Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations (538 views)
Proteins (ISSN: 0887-3585, 1097-0134, 1097-0134electronic), 2004 Sep 15; 56(3): 430-448.
Impact Factor: 4.429
View Export to BibTeX Export to EndNote
Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M
* In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (587 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2004 Mar; 45(3): 485-494.
Impact Factor: 5.362
View Export to BibTeX Export to EndNote
Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M
* In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (547 views)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004 Feb; 19(1): 93-98.
Impact Factor: 1.091
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (472 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (422 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (347 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (397 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas (352 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Impact Factor: 5.641
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzullo L, Ionna F, Mozzillo N, ListerJames J, Salvatore M
Somatostatin receptor scintigraphy (SRS) with technetium-99m labeled synthetic peptides in melanoma (386 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (234 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Muto P, Lastoria S, Vergara E, Caraco C, Varrella P, Bernardy JD, Acampa W, Salvatore M
Tc-99m labeled somatostatin analogs to image tumors expressing specific receptors (250 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (240 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
* Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences (19 views)
Neuroendocrinology (ISSN: 0028-3835linking), 2021; 111(7): 696-704.
Impact Factor: 4.271
View Export to BibTeX Export to EndNote
Lastoria S, Marciello F, Faggiano A, Aloj L, Caraco C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De LucaL, Fonti R, Napolitano V, Colao A
* Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) (259 views)
Endocrine (ISSN: 1355-008x), 2016 Jun; 52(3): 488-494.
Impact Factor: 3.131
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (334 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, Degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML
* Rare diseases in clinical endocrinology: A taxonomic classification system (1216 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2015; 38(2): 193-259.
Impact Factor: 1.994
View Export to BibTeX Export to EndNote
Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M
* Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma (333 views)
World J Radiol (ISSN: 1949-8470, 1949-8470electronic, 1949-8470linking), 2014 Oct 28; 6(10): 840-845.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (722 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (2014 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (354 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (541 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (432 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
View Export to BibTeX Export to EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (1177 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
View Export to BibTeX Export to EndNote
Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, Ruvo M, Gioia M, Rizzarelli E, Coletta M
* Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity (455 views)
J Mol Biol (ISSN: 1089-8638, 0022-2836, 1089-8638electronic), 2009 Feb 6; 385(5): 1556-1567.
Impact Factor: 3.871
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (572 views)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (479 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
View Export to BibTeX Export to EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (334 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
View Export to BibTeX Export to EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (323 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Vitale RM, Pedone C, De Benedetti PG, Fanelli F
* Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations (538 views)
Proteins (ISSN: 0887-3585, 1097-0134, 1097-0134electronic), 2004 Sep 15; 56(3): 430-448.
Impact Factor: 4.429
View Export to BibTeX Export to EndNote
Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M
* In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (587 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2004 Mar; 45(3): 485-494.
Impact Factor: 5.362
View Export to BibTeX Export to EndNote
Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M
* In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (547 views)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004 Feb; 19(1): 93-98.
Impact Factor: 1.091
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (472 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (422 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (347 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (397 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas (352 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Impact Factor: 5.641
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzullo L, Ionna F, Mozzillo N, ListerJames J, Salvatore M
Somatostatin receptor scintigraphy (SRS) with technetium-99m labeled synthetic peptides in melanoma (386 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (234 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Muto P, Lastoria S, Vergara E, Caraco C, Varrella P, Bernardy JD, Acampa W, Salvatore M
Tc-99m labeled somatostatin analogs to image tumors expressing specific receptors (250 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (240 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
46 Records (36 excluding Abstracts).
Total impact factor: 169.93 (137.566 excluding Abstracts).
Total 5 year impact factor: 168.085 (128.959 excluding Abstracts).
Total impact factor: 169.93 (137.566 excluding Abstracts).
Total 5 year impact factor: 168.085 (128.959 excluding Abstracts).
397 views. Last view on Saturday 27 May 2023, 10:43:33
ibb.cnr.it
